Nature Communications (Apr 2023)
Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques
- Laura Solforosi,
- Lea M. M. Costes,
- Jeroen T. B. M. Tolboom,
- Katherine McMahan,
- Tochi Anioke,
- David Hope,
- Tetyana Murdza,
- Michaela Sciacca,
- Emily Bouffard,
- Julia Barrett,
- Cindy Wu,
- Nicole Hachmann,
- Jessica Miller,
- Jingyou Yu,
- Xuan He,
- Catherine Jacob-Dolan,
- Sietske K. Rosendahl Huber,
- Liesbeth Dekking,
- Ronnie Chamanza,
- Ying Choi,
- Karin Feddes-de Boer,
- Dan H. Barouch,
- Hanneke Schuitemaker,
- Roland C. Zahn,
- Frank Wegmann
Affiliations
- Laura Solforosi
- Janssen Vaccines and Prevention B.V.
- Lea M. M. Costes
- Janssen Vaccines and Prevention B.V.
- Jeroen T. B. M. Tolboom
- Janssen Vaccines and Prevention B.V.
- Katherine McMahan
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Tochi Anioke
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- David Hope
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Tetyana Murdza
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Michaela Sciacca
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Emily Bouffard
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Julia Barrett
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Cindy Wu
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Nicole Hachmann
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Jessica Miller
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Jingyou Yu
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Xuan He
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Catherine Jacob-Dolan
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Sietske K. Rosendahl Huber
- Janssen Vaccines and Prevention B.V.
- Liesbeth Dekking
- Janssen Vaccines and Prevention B.V.
- Ronnie Chamanza
- Non-Clinical Safety Toxicology/Pathology, Janssen Research and Development
- Ying Choi
- Janssen Vaccines and Prevention B.V.
- Karin Feddes-de Boer
- Janssen Vaccines and Prevention B.V.
- Dan H. Barouch
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Hanneke Schuitemaker
- Janssen Vaccines and Prevention B.V.
- Roland C. Zahn
- Janssen Vaccines and Prevention B.V.
- Frank Wegmann
- Janssen Vaccines and Prevention B.V.
- DOI
- https://doi.org/10.1038/s41467-023-37715-2
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 14
Abstract
Variant booster vaccines are a strategy to improve protection against SARS-CoV-2. Here, the authors find that both Wuhan-Hu-1-based Ad26.COV2.S or an Omicron-adapted booster vaccine provide robust immune responses and protection against Omicron in NHP.
